Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesMay 16, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 16, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 14, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 14, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 14, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 14, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 14, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 13, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 12, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 12, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 12, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 12, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 12, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 5, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 5, 2014View HTMLDownload DOCDownload PDF
10-QQuarterly report which provides a continuing view of a company's financial positionMay 2, 2014View HTMLDownload DOCDownload PDFDownload XLSView XBRLDownload XBRL
8-KReport of unscheduled material events or corporate eventMay 1, 2014View HTMLDownload DOCDownload PDFDownload XLS
ARSAn annual report to security holders.Apr 24, 2014View HTMLDownload DOCDownload PDF
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 22, 2014View HTMLDownload DOCDownload PDFDownload XLS
DEFA14AAdditional proxy soliciting materials - definitiveApr 22, 2014View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesApr 1, 2014View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventMar 25, 2014View HTMLDownload DOCDownload PDFDownload XLS
3Initial filing by director officer or owner of more than ten percent.Mar 21, 2014View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 21, 2014View HTMLDownload DOCDownload PDF
NO ACTNo Action LettersMar 14, 2014View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-125      126-137

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information